Search Results for: Terapia antibiotica: breve durata vs. lunga durata

Annals of Internal Medicine, Ahead of Print.

Annals of Internal Medicine, Ahead of Print.

Annals of Internal Medicine, Ahead of Print.

Annals of Internal Medicine, Ahead of Print.

Mixed urinary incontinence presents a clinical conundrum. Patients with mixed urinary incontinence report symptoms of both stress incontinence (loss of urine with exertion) and urge incontinence (loss of urine with urgency). Mixed urinary incontinence is a combination of the two that affects 37% of women older than age 65 years. The personal and societal costs of incontinence are significant. In women with symptoms of severe urinary incontinence, the cost of supplies, laundry, and dry cleaning range from $900 to $4000 annually. By 80 years of age, 20% of women will undergo surgery for stress or mixed urinary incontinence. Physical and behavioral therapy improves both incontinence types, and medications are standard treatment for urgency urinary incontinence. When conservative therapies fail, conventional guidance has been to treat the urgency prior to the stress component of mixed incontinence, because anti-incontinence surgical procedures can worsen urgency incontinence, and many urgency treatments are medical rather than surgical. Another strategy has been to treat whichever symptom is dominant.

This clinical trial compares the efficacy of intradetrusor onabotulinumtoxinA vs midurethral sling for the treatment of mixed urinary incontinence in females.

In a comparative study, AI-generated and physician-written summaries each had unique strengths and weaknesses.

Si adotta a comparsa mutazione gene,prima che neoplasia peggiori

This randomized clinical trial compares the effectiveness of initiating oral naltrexone vs extended-release injectable naltrexone on reduction in alcohol use and health care utilization among medical inpatients with alcohol use disorder.

This cohort study examines the imaging quality and time efficiency of a novel autonomous total body photographic and dermoscopic device compared with traditional manual digital dermoscopic imaging.

In the Original Investigation titled “Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial,” published online December 19, 2024, and in the February 2025 issue, there were errors in the Key Points and Table 1. In the Key Points Findings section, the percentage of patients with macrovascular invasion was updated to 74%. In Table 1, the values in the HCC volume/liver volume row were updated to percentages. This article was corrected online.

This Viewpoint asserts that the formulation (tablet vs capsule) and the dosage of cabozantinib can be optimized to reduce toxicities and cost while maintaining efficacy.

This case-control study investigates if a regional homogeneity–magnetic resonance imaging cortical deficit pattern provides a more robust biomarker for major depressive disorder (MDD) than its structural counterpart and informs the underlying, regionally specific lower cerebral blood flow in this disorder.

This randomized clinical trial assesses the efficacy of a pharmacist-led transition of care program in reducing emergency department visits related to the same medication-related event at 6 months compared with usual care.

In Reply Ballhausen and Modest express concerns about our conclusions on the primary end point, progression-free survival (PFS), and overall survival (OS), a secondary end point of the CAIRO5 randomized clinical trial. PFS has been considered a valid surrogate end point for OS based on data from 22 metastatic colorectal cancer (mCRC) trials. Although this result was irrespective of the use of biologic agents, they mention a lack of this correlation in more recent trials comparing anti–vascular endothelial growth factor vs anti–epidermal growth factor receptor antibodies added to chemotherapy. We clearly stated that OS in the CAIRO5 trial was a secondary end point and that its analysis was underpowered. However, in both comparisons, the OS difference was marginal, with survival curves crossing several times in the bevacizumab/panitumumab comparison. Therefore, we consider it unlikely that additional events would reveal clinically meaningful OS differences. As to the comparison of folinic acid, 5-fluorouracil, oxaliplatin and irinotecan (FOLFOXIRI) vs folinic acid (leucovorin), fluorouracil, and oxaliplatin (FOLFOX)/folinic acid (leucovorin), fluorouracil, and irinotecan (FOLFIRI), both with bevacizumab, we have previously questioned the clinical significance of the observed statistically significant 1.6-month benefit in median PFS in favor of FOLFOXIRI. We suggested that FOLFOXIRI would only be preferred when the observed increase in complete local treatments would translate into a benefit in OS, which was not the case. Ballhausen and Modest suggest that PFS/OS events may be influenced by local liver treatment rather than failure of systemic treatment. However, conversion to local liver treatment may also be affected by the systemic treatment regimen. Because the ability to undergo local treatment cannot be predicted before initiating systemic treatment, this remains an inherent aspect of studies in patients with initially unresectable liver metastases.

This randomized clinical trial compares the efficacy and safety of atezolizumab plus trastuzumab plus capecitabine and oxaliplatin chemotherapy (XELOX) vs trastuzumab plus XELOX in Chinese patients with locally advanced human epidermal growth factor receptor 2 (ERBB2)–positive gastric cancer or adenocarcinoma of the gastroesophageal junction.